Role of EGFR-TKIs in Nonmetastatic Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: A Comprehensive Review - PubMed
4 hours ago
- #EGFR-TKIs
- #NSCLC
- #Osimertinib
- EGFR-TKIs have revolutionized the treatment of EGFR-mutated NSCLC.
- Osimertinib, a third-generation EGFR TKI, is now the standard of care for most stages of EGFR-mutated NSCLC.
- The ADAURA trial showed adjuvant osimertinib improves DFS and OS in resected stage IB-IIIA NSCLC.
- The LAURA trial established osimertinib as consolidation therapy after chemoradiotherapy in unresectable stage III EGFR-mutated NSCLC.
- Osimertinib reduces CNS relapse rates but has potential toxicities like rash, diarrhea, and interstitial lung disease.
- Future research focuses on perioperative osimertinib use and extending TKI therapy to other oncogenic drivers like ALK, ROS1, and RET.